Fox Chase Researchers Underscore Efficacy of Pembrolizumab Plus Axitinib in Treating Advanced Renal Cell Carcinoma
PHILADELPHIA (May 29, 2020)—Pembrolizumab (Keytruda) in combination with axitinib (Inlyta) continues to show improved efficacy in the treatment of advanced renal cell carcinoma when compared with the use of sunitinib (Sutent).